Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NUVL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNuvalent submits first NDA to FDA for neladalkib in ALK-positive lung cancer
Filed April 7, 2026 · Period ending April 7, 2026 · ~1 min read
Key Changes
-
high
Company filed New Drug Application with FDA for neladalkib to treat advanced ALK-positive non-small cell lung cancer in patients previously treated with tyrosine kinase inhibitors
Item 8.01 verify on EDGAR → -
high
NDA submission marks first product candidate to reach regulatory filing stage for the company
Item 8.01 verify on EDGAR →
Summary
Nuvalent filed its first New Drug Application with the FDA for neladalkib, targeting patients with advanced ALK-positive non-small cell lung cancer who have already received tyrosine kinase inhibitor treatment. This regulatory submission represents a critical milestone for the company, moving its lead candidate from clinical development into the FDA review process that could lead to commercial approval. For investors, the NDA filing shifts Nuvalent from a pure clinical-stage company to one with a product under regulatory review.
The FDA will now evaluate the application to determine whether neladalkib's efficacy and safety data support approval for this patient population. The timeline for FDA review and the agency's eventual decision will be key factors to watch as they will determine whether Nuvalent can begin generating product revenue.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 7, 2026, Nuvalent, Inc. announced the submission of its New Drug Application to the U.S. Food and Drug Administration for neladalkib in tyrosine kinase inhibitor pre-treated advanced ALK-positive non-small cell lung cancer.
Nuvalent submitted a New Drug Application to the FDA for neladalkib, a treatment for patients with advanced ALK-positive non-small cell lung cancer who have previously been treated with tyrosine kinase inhibitors. This regulatory filing is a critical milestone toward potential commercial approval and represents the company's first product candidate to reach this stage.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 23, 2026 · How we verify